Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLID-TIMI 52: Darapladib in Acute Coronary Syndrome
NCT01000727Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2009
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Darapladib with Placebo (2 arms). Primary endpoint: Composite of Major Coronary Events (CHD Death, MI, Urgent Coronary Revascularization) at 3.8 years. Started Dec 2009; status: completed.
02
Drugs
darapladib
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT01000727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000727.